Efficacy Study of Crizotinib in East Asian Patients With ROS1-Positive, ALK-Negative Advanced NSCLC
Phase-2, Open-Label, Single-Arm Study of the Efficacy and Safety of Crizotinib in East Asian Patients with Advanced ALK-Negative Non-Small Cell Lung Cancer (NSCLC) Harboring a Translocation or Inversion Involving the C-ROS Oncogene (ROS1) Locus
Category & Conditions: Cancer
Medicine: XALKORI®(CRIZOTINIB)
ClinicalTrials.gov Identifier (NCT): NCT01945021
Protocol ID: A8081063
PrintDownloadOpen Plain Language Summary Result: Click here